Table 2

Overall results of the included trials

First authorRittmeyer et al
(OAK)9
Herbst et al
(KEYNOTE-010)8
Borghaei et al (CheckMate 057)11Brahmer et al
(CheckMate 017)10
ImmunotherapyAtezolizumabPembrolizumabNivolumabNivolumab
 Number of patients on immunotherapy (experimental group)425690
(2 mg/kg=344, 10 mg/kg=346)
292135
Number of patients on chemotherapy
(control group)
425343290137
Follow-up (months)21 (median)13.1 (median)13.1 (minimum)11.0 (minimum)
Median number of chemotherapy cycles2.1 months2.0 months (0.8–3.6)Four cycles (range: 1–23)Three cycles (range: 1–29)
Overall survival (OS)Events:
Atezolizumab: 271
Docetaxel: 298
Median OS:
13.8 months (experimental) versus 9.6 months (docetaxel)
HR=0.73
(95% CI 0.62 to 0.87) p=0.0003
Events:
Pembrolizumab 2 mg/kg: 172
Pembrolizumab 10 mg/kg: 156
Docetaxel: 193
Median OS:
10.4 months (pembrolizumab 2 mg/kg), 12.7 months (pembrolizumab 10 mg/kg) versus 8.5 months (docetaxel)
HR for pembrolizumab
2 mg/kg versus docetaxel=0.71
(95% CI 0.58 to 0.88) p=0.0008)
HR for pembrolizumab 10 mg/kg versus docetaxel=0.61
(95% CI 0.49 to 0.75) p<0.0001
Events:
Nivolumab: 190
Docetaxel: 223
Median OS:
12.2 months (experimental) versus 9.4 months (docetaxel)
HR=0.73
(95% CI 0.59 to 0.89) p=0.002
Events:
Nivolumab: 86
Docetaxel: 113
Median OS:
9.2 months (experimental) versus 6.0 months (docetaxel)
HR=0.59
(95% CI 0.44 to 0.79)
p<0.001
Progression-free survival (PFS)Events:
Not reported
Median PFS:
2.8 months (experimental) versus 4.0 months (docetaxel)
HR=0.95
(95% CI 0.82 to 1.10) p=0.493
Events:
Experimental:
Pembrolizumab (2 mg/kg): 266
Pembrolizumab (10 mg/kg): 254
Docetaxel: 256
Median PFS:
3.9 months (pembrolizumab 2 mg/kg), 4.0 months (pembrolizumab 10 mg/kg) versus 4.0 months in the docetaxel group
HR=0.88 for pembrolizumab
2 mg/kg versus docetaxel
(95% CI 0.74 to 1.05) p=0.07:
HR=0.79 for pembrolizumab 10 mg/kg versus docetaxel
(95% CI 0.66 to 0.94) p=0.004
Events:
Experimental: 234
Docetaxel: 245
Median PFS:
2.3 months (nivolumab) versus 4.2 months (docetaxel)
HR=0.92 (95% CI 0.77 to 1.10) p=0.39
Events:
Experimental: 105
Docetaxel: 122
Median PFS:
3.5 months (experimental) versus 2.8 months (docetaxel)
HR=0.62
(95% CI 0.47 to 0.81) p<0.001
Overall response rate (n (%))Experimental: 58 (14)
Docetaxel: 57 (13)
Experimental:
62 (18). p=0.0005 for 2 mg/kg.
64 (18). p=0.0002 for 10 mg/kg
Docetaxel: 32 (9)
Experimental: 56 (19)
Docetaxel: 36 (12)
Experimental: 27 (20%)
Docetaxel: 12 (9%).
Duration of responseMedian:
16.3 months (atezolizumab) versus 6.2 months (docetaxel)
HR=0.34 (95% CI 0.21 to 0.55) p<0.00001
Median: not reached (both doses of pembrolizumab) versus 8 months (docetaxel).
HR*=0.28 (95% CI 0.15 to 0.53)
For pembrolizumab 2 mg/kg versus docetaxel, p<0.0001
HR*:0.29 (95% CI 0.15 to 0.55)
For pembrolizumab 10 mg/kg versus docetaxel, p<0.0001
Median:
17.2 months (nivolumab) versus 5.6 months (docetaxel)
HR*=0.32 (95% CI 0.13 to 0.83) p=0.02
Median:
Not reached (nivolumab) versus 8.4 months (docetaxel)
HR*=0.39 (95% CI 0.20 to 0.79) p=0.008
Treatment-related adverse event (grades III–V) (n (%))Atezolizumab: 90 (15):
Fatigue 17 (2.8)
Dyspnoea: 15 (2.5)
Anaemia: 14 (2.3)
Docetaxel: 247 (43):
Neutropaenia: 75 (13).
Febrile neutropaenia: 62 (10.7)
Anaemia: 33 (5.7)
Pembrolizumab:
2 mg/kg: 43 (13)
10 mg/kg: 55 (16):
Fatigue:
2 mg/kg: 4 (1)
10 mg/kg: 6 (2)
Pneumonitis:
2 mg/kg: 7 (2)
10 mg/kg: 7 (2)
Severe skin reactions:
2 mg/kg: 3 (1)
10 mg/kg: 6 (2)
Docetaxel: 109 (35):
Fatigue: 11 (4)
Diarrhoea: 7 (2)
Asthenia: 6 (2)
Anaemia: 5 (2)
Neutropaenia: 38 (12)
Nivolumab: 30 (10):
Fatigue: 3 (1)
Nausea: 2 (1)
Diarrhoea: 2 (1)
Docetaxel: 144 (54):
Neutropaenia: 83 (31)
Febrile neutropaenia: 26 (10)
Leucopaenia: 22 (8)
Nivolumab: 9 (7):
Fatigue: 1 (1)
Decrease appetite: 1 (1)
Leucopaenia: 1 (1)
Docetaxel: 71 (55):
Neutropaenia: 38 (30)
Febrile neutropaenia: 13 (10)
Fatigue: 10 (8)
Discontinuation rate (n (%))Atezolizumab: 46 (8)
Docetaxel: 108 (19)
Pembrolizumab (2 mg/kg):
15 (4)
Pembrolizumab (10 mg/kg):
17 (5)
Docetaxel: 31 (10)
Nivolumab: (5)
Docetaxel: (15)
Nivolumab: (3)
Docetaxel: (10)
  • *Calculated from data.